187 related articles for article (PubMed ID: 16504266)
1. Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder.
Yamasaki Y; Smith C; Weisz D; van Huizen I; Xuan J; Moussa M; Stitt L; Hideki S; Cherian MG; Izawa JI
Urology; 2006 Mar; 67(3):530-5. PubMed ID: 16504266
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
3. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
4. [Clinical prognostic factors in superficial cancer of the urinary bladder].
Busto Catañón L; Sánchez Merino JM; Picallo Sánchez JA; Gelabert Mas A
Arch Esp Urol; 2001 Mar; 54(2):131-8. PubMed ID: 11341116
[TBL] [Abstract][Full Text] [Related]
5. Expression of p27 and its ubiquitin ligase subunit Skp2 in upper urinary tract transitional cell carcinoma.
Langner C; von Wasielewski R; Ratschek M; Rehak P; Zigeuner R
Urology; 2004 Sep; 64(3):611-6. PubMed ID: 15351619
[TBL] [Abstract][Full Text] [Related]
6. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
[TBL] [Abstract][Full Text] [Related]
7. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder.
Daneshmand S; Stein JP; Lesser T; Quek ML; Nichols PW; Miranda G; Cai J; Groshen S; Skinner EC; Skinner DG
J Urol; 2004 Jul; 172(1):81-4. PubMed ID: 15201742
[TBL] [Abstract][Full Text] [Related]
10. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
11. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
12. Identification of bladder cancer patients at risk for recurrence or progression: an immunohistochemical study based on the expression of metallothionein.
Hinkel A; Schmidtchen S; Palisaar RJ; Noldus J; Pannek J
J Toxicol Environ Health A; 2008; 71(13-14):954-9. PubMed ID: 18569601
[TBL] [Abstract][Full Text] [Related]
13. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer.
Boorjian S; Ugras S; Mongan NP; Gudas LJ; You X; Tickoo SK; Scherr DS
Urology; 2004 Aug; 64(2):383-8. PubMed ID: 15302512
[TBL] [Abstract][Full Text] [Related]
16. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
17. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.
Tokunaga H; Lee DH; Kim IY; Wheeler TM; Lerner SP
Clin Cancer Res; 1999 Sep; 5(9):2520-5. PubMed ID: 10499628
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of pathologic stage T0 on organ-confined bladder transitional cell carcinoma following radical cystectomy.
Cho KS; Seo JW; Park SY; Cho NH; Choi YD; Yang SC; Hong SJ
Urol Int; 2008; 81(4):394-8. PubMed ID: 19077398
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
